Safety of Duloxetine During Pregnancy: Recent Findings

Study Overview

A recent study explored the safety of using the antidepressant duloxetine during pregnancy, particularly regarding its impact on unborn children. Duloxetine is utilized for various conditions, including pain, depression, and anxiety, which are common among pregnant women. However, the debate surrounding the benefits and risks of this medication in such a vulnerable demographic continues.

Conflicting Research

Prior research presents mixed findings. A Danish study indicated a potential increased risk of spontaneous abortion associated with duloxetine use, while another multicenter study reported that the rate of malformations was consistent with expected levels within the population.

Objectives of the Recent Study

The authors of the latest study, published in the British Medical Journal, aimed to fill the gap in large-scale research concerning congenital defects linked to duloxetine use during pregnancy among mothers aged 18 to 55. Utilizing data from the Medicaid Analytic eXtract (MAX) database, the study analyzed publicly insured pregnancies in the United States from 2004 to 2013. Given that around 50% of the U.S. population relies on Medicaid for pregnancy-related expenses, this database provided a substantial sample size, with cohorts ranging from 1.3 million to 4.1 million participants.

Methodology and Findings

The research compared control groups with pregnant women who used duloxetine. Through raw analyses and adjustments for potential confounding factors—such as comorbid medical conditions, maternal age, and other medications—the findings suggested that duloxetine use may elevate the risk of postpartum hemorrhage and cardiac malformations. Conversely, the study indicated that this antidepressant does not significantly affect the rates of preterm birth, congenital malformations, or pre-eclampsia.

Limitations and Considerations

Despite the findings, the authors acknowledged several limitations of the study. Large healthcare databases can inadvertently misclassify information, and the data’s scope may be restricted. For example, while the database records prescription information, it does not confirm actual medication usage. The identification of major congenital malformations relied on reimbursement codes, which may not capture all relevant cases. Additionally, unexamined factors could potentially confound the results. Nonetheless, the researchers conducted multiple sensitivity analyses to mitigate some of these limitations.

Conclusions and Future Research

The authors urged caution regarding the conclusions drawn from their study, recommending that future research is necessary to validate these results.

Reference

Huybrechts KF et al. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ. 2020;368:m237. doi:http://dx.doi.org/10.1136/bmj.m237

Written by Olajumoke Marissa Ologundudu, B.Sc. (Hons)

Image by Pexels from Pixabay